Glycomimetics Inc (GLYC) Stock Price, Quote & News

Latest News on GLYC

Nov 12, 2024, 8:00 AM EST - 2 months ago

Crescent Biopharma to Present at Jefferies London Healthcare Conference 2024

Nov 6, 2024, 7:00 AM EST - 2 months ago

GlycoMimetics Announces New Uproleselan Clinical Data Will Be Presented at ASH Annual Meeting

Oct 31, 2024, 11:57 AM EDT - 2 months ago

GLYCOMIMETICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of GlycoMimetics, Inc. - GLYC

Oct 29, 2024, 11:47 AM EDT - 2 months ago

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PFIE and GLYC on Behalf of Shareholders

PFIE

Oct 29, 2024, 7:00 AM EDT - 2 months ago

GlycoMimetics Enters Into Acquisition Agreement With Crescent Biopharma

Oct 29, 2024, 6:30 AM EDT - 2 months ago

GlycoMimetics Announces National Cancer Institute Phase 2/3 Study of Uproleselan Did Not Meet Primary Endpoint

Jul 25, 2024, 9:00 AM EDT - 6 months ago

GlycoMimetics Announces Strategic Review and Corporate Restructuring Plan

$GlycoMimetics Announces Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)$

Jun 4, 2024, 7:00 AM EDT - 8 months ago

GlycoMimetics Announces Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

$GlycoMimetics to Host Key Opinion Leader Event to Review Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) on June 4, 2024$

May 29, 2024, 4:01 PM EDT - 8 months ago

GlycoMimetics to Host Key Opinion Leader Event to Review Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) on June 4, 2024

May 9, 2024, 3:17 PM EDT - 9 months ago

GlycoMimetics, Inc. (GLYC) Corporate Update Call Transcript

$GlycoMimetics Announces Results of Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)$

May 6, 2024, 6:00 AM EDT - 9 months ago

GlycoMimetics Announces Results of Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Apr 30, 2024, 7:42 AM EDT - 9 months ago

GlycoMimetics: Is No News Bad News?

Apr 25, 2024, 7:00 AM EDT - 9 months ago

GlycoMimetics to Report First Quarter 2024 Financial Results on May 9, 2024

Mar 27, 2024, 10:27 AM EDT - 10 months ago

GlycoMimetics, Inc. (GLYC) Q4 2023 Earnings Call Transcript

Mar 27, 2024, 7:00 AM EDT - 10 months ago

GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2023

Mar 21, 2024, 5:47 PM EDT - 10 months ago

GlycoMimetics Can Become A Game Changer In Blood Cancers

Mar 13, 2024, 7:00 AM EDT - 11 months ago

GlycoMimetics to Report Fourth Quarter and 2023 Full Year Financial Results on March 27, 2024

Feb 26, 2024, 7:00 AM EST - 11 months ago

GlycoMimetics to Participate in Upcoming Cowen 44th Annual Health Care Conference

Feb 12, 2024, 7:00 AM EST - 1 year ago

GlycoMimetics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Jan 30, 2024, 1:04 PM EST - 1 year ago

GlycoMimetics: Drug Approval Is Not Coming In 2024, But The Hype Could Be Real

Jan 4, 2024, 7:00 AM EST - 1 year ago

GlycoMimetics Announces Positive Initial Safety and Pharmacokinetic Results from Phase 1a Healthy Volunteer Study of GMI-1687

Dec 10, 2023, 12:00 PM EST - 1 year ago

GlycoMimetics Announces Independent Presentations on Uproleselan at American Society of Hematology Annual Meeting including New Clinical Data in Treated Secondary Acute Myeloid Leukemia

Nov 9, 2023, 7:00 AM EST - 1 year ago

GlycoMimetics to Participate in Upcoming Jefferies London Healthcare Conference

Nov 3, 2023, 12:24 PM EDT - 1 year ago

GlycoMimetics, Inc. (GLYC) Q3 2023 Earnings Call Transcript

Nov 3, 2023, 7:00 AM EDT - 1 year ago

GlycoMimetics Reports Highlights and Financial Results for Third Quarter 2023

Oct 20, 2023, 7:00 AM EDT - 1 year ago

GlycoMimetics to Report Third Quarter 2023 Financial Results on November 3, 2023

Sep 6, 2023, 7:00 AM EDT - 1 year ago

GlycoMimetics Announces First Cohort Dosed in Human Phase 1a Study of GMI-1687

Sep 5, 2023, 7:00 AM EDT - 1 year ago

GlycoMimetics to Participate in Upcoming H.C. Wainwright 25th Annual Global Investment Conference

Aug 17, 2023, 7:00 AM EDT - 1 year ago

GlycoMimetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Aug 14, 2023, 8:55 AM EDT - 1 year ago

GlycoMimetics: Q2 2024 Data Readout Makes This Worth A Look, But Cash Is A Problem

Aug 2, 2023, 1:09 PM EDT - 1 year ago

GlycoMimetics, Inc. (GLYC) Q2 2023 Earnings Call Transcript

Aug 2, 2023, 7:00 AM EDT - 1 year ago

GlycoMimetics Reports Highlights and Financial Results for Second Quarter 2023

Jul 19, 2023, 7:00 AM EDT - 1 year ago

GlycoMimetics to Report Second Quarter 2023 Financial Results on August 2, 2023

Jun 26, 2023, 8:00 AM EDT - 1 year ago

GlycoMimetics Announces Its Addition to the Russell Microcap® Index

$GlycoMimetics Announces U.S. Food and Drug Administration Clears Addition of Time-based Final Analysis to Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory Acute Myeloid Leukemia$